Beacon Therapeutics to advance ocular disease treatment
Biotechnology company Beacon Therapeutics has raised over $75 million to advance treatments for ocular diseases. The funding was raised in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of… Read More
